TREM-2 and tumors

doi:10.3760/cma.j.cn371439-20200611-00019

Abstract

Abstract:

Triggering receptors expressed on myeloid cells-2 (TREM-2) is a newly discovered immunoglobulin receptor, which plays an important role in inflammation and immunoreaction. Several recent studies have shown that TREM-2 is aberrantly expressed in various types of cancers such as lung cancer, gastric cancer, liver cancer, colorectal cancer, renal carcinoma and glioma, and it is widely participated in regulating malignant tumor initiation, progression, invasion and metastasis through different signal pathways. TREM-2 is expected to provide evidence for the diagnosis and treatment of malignant tumors.

Key words: Neoplasms, Prognosis, Triggering receptors expressed on myeloid cells-2

Li Liting, Gao Xiaoling. TREM-2 and tumors[J]. Journal of International Oncology, 2021, 48(2): 101-104.

References 29

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi: 10.3322/caac.21492 pmid: 30207593
[2]	Poliani PL, Wang Y, Fontana E, et al. TREM2 sustains microglial expansion during aging and response to demyelination[J]. J Clin Invest, 2015,125(5):2161-2170. DOI: 10.1172/JCI77983. pmid: 25893602
[3]	Zhong L, Chen XF, Zhang ZL, et al. DAP12 stabilizes the C-terminal fragment of the triggering receptor expressed on myeloid cells-2 (TREM2) and protects against LPS-induced pro-inflammatory response[J]. J Biol Chem, 2015,290(25):15866-15877. DOI: 10.1074/jbc.M115.645986. doi: 10.1074/jbc.M115.645986 pmid: 25957402
[4]	Shi Y, Holtzman DM. Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight[J]. Nat Rev Immunol, 2018,18(12):759-772. DOI: 10.1038/s41577-018-0051-1. doi: 10.1038/s41577-018-0051-1 pmid: 30140051
[5]	Katsel P, Haroutunian V. Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old[J]. Dialogues Clin Neurosci, 2019,21(1):7-19. DOI: 10.31887/DCNS.2019.21.1/vharoutunian. pmid: 31607776
[6]	Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis[J]. Nat Rev Neurosci, 2016,17(4):201-207. DOI: 10.1038/nrn.2016.7. doi: 10.1038/nrn.2016.7 pmid: 26911435
[7]	孙可欣, 郑荣寿, 张思维. 2015年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2019,28(1):1-11. DOI: 10.11735/j.issn.1004-0242.2019.01.A001.
[8]	潘志杰. 负向免疫调控分子TREM-2在肺癌发病中作用及机制的研究[D]. 杭州: 浙江大学, 2013.
[9]	Yao Y, Li H, Chen J, et al. TREM-2 serves as a negative immune regulator through Syk pathway in an IL-10 dependent manner in lung cancer[J]. Oncotarget, 2016,7(20):29620-29634. DOI: 10.18632/oncotarget.8813. doi: 10.18632/oncotarget.8813 pmid: 27102437
[10]	Thomson AW, Metes DW, Ezzelarab MB, et al. Regulatory dendri-tic cells for human organ transplantation[J]. Transplant Rev (Orlando), 2019,33(3):130-136. DOI: 10.1016/j.trre.2019.05.001. doi: 10.1016/j.trre.2019.05.001
[11]	Hamerman JA, Jarjoura JR, Humphrey MB, et al. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12[J]. J Immunol, 2006,177(4):2051-2055. DOI: 10.4049/jimmunol.177.4.2051. doi: 10.4049/jimmunol.177.4.2051 pmid: 16887962
[12]	Zhu M, Wang Q, Luo Z, et al. Development and validation of a prognostic signature for preoperative prediction of overall survival in gastric cancer patients[J]. Onco Targets Ther, 2018,11:8711-8722. DOI: 10.2147/OTT.S181741. doi: 10.2147/OTT.S181741 pmid: 30584329
[13]	Zhang X, Wang W, Li P, et al. High TREM2 expression correlates with poor prognosis in gastric cancer[J]. Hum Pathol, 2018,72:91-99. DOI: 10.1016/j.humpath.2017.10.026. doi: 10.1016/j.humpath.2017.10.026 pmid: 29104108
[14]	冯春念, 马婷婷, 赵千秋, 等. 胃癌组织TREM2表达变化及其临床意义[J]. 山东医药, 2018,58(44):78-80. DOI: 10.3969/j.issn.1002-266X.2018.44.023.
[15]	Zhang SL, Chen TS, Xiao L, et al. TREM2 siRNA inhibits cell proliferation of human liver cancer cell lines[J]. Int J Clin Exp Pathol, 2016,9(4):4318-4328.
[16]	Tang W, Lv B, Yang B, et al. TREM2 acts as a tumor suppressor in hepatocellular carcinoma by targeting the PI3K/Akt/β-catenin pathway[J]. Oncogenesis, 2019,8(2):9. DOI: 10.1038/s41389-018-0115-x. doi: 10.1038/s41389-018-0115-x pmid: 30683932
[17]	Wands JR, Kim M. WNT/β-catenin signaling and hepatocellular carcinoma[J]. Hepatology, 2014,60(2):452-454. DOI: 10.1002/hep.27081. doi: 10.1002/hep.27081 pmid: 24644061
[18]	Peng Q, Malhotra S, Torchia JA, et al. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1[J]. Sci Signal, 2010,3(122):ra38. DOI: 10.1126/scisignal.2000500. doi: 10.1126/scisignal.2000500 pmid: 20484116
[19]	Genua M, Monico MC, D'Alessio S, et al. Intestinal microbiota defined by the absence of the triggering receptor expressed on myeloid cells type-2 (TREM-2) is transmissible and protects from colitis associated cancer[J]. Gastroenterology, 2014,146(5 suppl 1):S42. DOI: 10.1016/S0016-5085(14)60144-X.
[20]	Kim SM, Kim EM, Ji KY, et al. TREM2 acts as a tumor suppressor in colorectal carcinoma through Wnt1/β-catenin and Erk signaling[J]. Cancers (Basel), 2019,11(9):1315. DOI: 10.3390/can-cers11091315. doi: 10.3390/cancers11091315
[21]	Hsieh JJ, Purdue MP, Signoretti S, et al. Renal cell carcinoma[J]. Nat Rev Dis Primers, 2017,3:17009. DOI: 10.1038/nrdp.2017.9. doi: 10.1038/nrdp.2017.9 pmid: 28276433
[22]	Zhang H, Sheng L, Tao J, et al. Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway[J]. Int J Oncol, 2016,49(6):2498-2506. DOI: 10.3892/ijo.2016.3740. doi: 10.3892/ijo.2016.3740 pmid: 27779645
[23]	周伟敏. PDK1通过PI3K/AKT信号通路介导肾细胞癌生物学行为及机制研究[D]. 南昌: 南昌大学, 2019.
[24]	Sun M, Zhu M, Chen k, et al. TREM-2 promotes host resistance against pseudomonas aeruginosa infection by suppressing corneal inflammation via a PI3K/Akt signaling pathway[J]. Invest Ophthalmol Vis Sci, 2013,54(5):3451-3462. DOI: 10.1167/iovs.12-10938. doi: 10.1167/iovs.12-10938 pmid: 23611998
[25]	Zhu M, Li D, Wu Y, et al. TREM-2 promotes macrophage-mediated eradication of pseudomonas aeruginosa via a PI3K/Akt pathway[J]. Scand J Immunol, 2014,79(3):187-196. DOI: 10.1111/sji.12148. doi: 10.1111/sji.12148
[26]	Malaney P, Uversky VN, Davé V. PTEN proteoforms in biology and disease[J]. Cell Mol Life Sci, 2017,74(15):2783-2794. DOI: 10.1007/s00018-017-2500-6. doi: 10.1007/s00018-017-2500-6 pmid: 28289760
[27]	Fruman DA, Chiu H, Hopkins BD, et al. The PI3K pathway in human disease[J]. Cell, 2017,170(4):605-635. DOI: 10.1016/j.cell.2017.07.029. doi: 10.1016/j.cell.2017.07.029 pmid: 28802037
[28]	Wang XQ, Tao BB, Li B, et al. Overexpression of TREM2 enhances glioma cell proliferation and invasion: a therapeutic target in human glioma[J]. Oncotarget, 2016,7(3):2354-2366. DOI: 10.18632/oncotarget.6221. doi: 10.18632/oncotarget.6221 pmid: 26506595
[29]	Maru SV, Holloway KA, Flynn G, et al. Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation[J]. J Neuroimmunol, 2008,199(1-2):35-45. DOI: 10.1016/j.jneuroim.2008.04.029. doi: 10.1016/j.jneuroim.2008.04.029 pmid: 18538864

TREM-2 and tumors

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 29

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.